RE: NEWS!As well as the news about eniluracil, which essentially says that for one million dollars [on March 1] GSK drops it's option to buy back the rights to eniluracil, Peters acknoledeged that the money vault was empty by the end of March and that more will be needed to continue, which addresses all the concerns of the shareholders. We all feel the science is good otherwise we would not be here but the lack of money concerns us all and if Peters solves that problem without too much dilution the share price will reflect our belief.
The last paragraph from the NR this am. is below.
Regards, DH
"Adherex has indicated previously that we believe our cash and cash equivalents will be sufficient to satisfy our anticipated capital requirements into March 2007. The payment of the upfront fee to GSK does not alter our guidance, but we recognize the immediate need for additional capital to continue moving our product candidates forward in their development."